120 related articles for article (PubMed ID: 17545521)
21. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
Domingo-Domenech J; Oliva C; Rovira A; Codony-Servat J; Bosch M; Filella X; Montagut C; Tapia M; Campás C; Dang L; Rolfe M; Ross JS; Gascon P; Albanell J; Mellado B
Clin Cancer Res; 2006 Sep; 12(18):5578-86. PubMed ID: 17000695
[TBL] [Abstract][Full Text] [Related]
22. Vascular endothelial growth factor (VEGF) in sera of oral and oropharyngeal squamous cell carcinoma patients.
Friedrich RE; Klapdor R; Hagel C; Bartel-Friedrich S
Anticancer Res; 2010 May; 30(5):1765-6. PubMed ID: 20592375
[TBL] [Abstract][Full Text] [Related]
23. Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma.
Mitsuhashi A; Suzuka K; Yamazawa K; Matsui H; Seki K; Sekiya S
Cancer; 2005 Feb; 103(4):724-30. PubMed ID: 15637689
[TBL] [Abstract][Full Text] [Related]
24. Biological markers and prognosis in recurrent oral cancer after salvage surgery.
Agra IM; Carvalho AL; Pinto CA; Martins EP; Filho JG; Soares FA; Kowalski LP
Arch Otolaryngol Head Neck Surg; 2008 Jul; 134(7):743-9. PubMed ID: 18645125
[TBL] [Abstract][Full Text] [Related]
25. Vascular endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell carcinomas of the head and neck.
Sauter ER; Nesbit M; Watson JC; Klein-Szanto A; Litwin S; Herlyn M
Clin Cancer Res; 1999 Apr; 5(4):775-82. PubMed ID: 10213212
[TBL] [Abstract][Full Text] [Related]
26. Vesnarinone inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing the expression of vascular endothelial growth factor and interleukin-8.
Harada K; Supriatno ; Yoshida H; Sato M
Int J Oncol; 2005 Dec; 27(6):1489-97. PubMed ID: 16273203
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of vascular endothelial growth factor protein levels in T1-2 N0 laryngeal cancer treated with primary radiation therapy.
Parikh RR; Yang Q; Haffty BG
Cancer; 2007 Feb; 109(3):566-73. PubMed ID: 17183558
[TBL] [Abstract][Full Text] [Related]
28. Vascular endothelial growth factor a and proliferation marker in prediction of lymph node metastasis in oral and pharyngeal squamous cell carcinoma.
Boonkitticharoen V; Kulapaditharom B; Leopairut J; Kraiphibul P; Larbcharoensub N; Cheewaruangroj W; Chintrakarn C; Pochanukul L
Arch Otolaryngol Head Neck Surg; 2008 Dec; 134(12):1305-11. PubMed ID: 19075127
[TBL] [Abstract][Full Text] [Related]
29. [Relationship and expression of hepatocyte growth factor and vascular endothelial growth factor in serum preoperative and postoperative patients with laryngeal squamous cell cancer].
Wang Y; Zhao H; Chen J; Liu L; Zhang P; Che J; Wang G
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Dec; 24(24):1112-5. PubMed ID: 21395178
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie.
Negrier S; Perol D; Menetrier-Caux C; Escudier B; Pallardy M; Ravaud A; Douillard JY; Chevreau C; Lasset C; Blay JY;
J Clin Oncol; 2004 Jun; 22(12):2371-8. PubMed ID: 15197198
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer.
Kulke MH; Odze RD; Mueller JD; Wang H; Redston M; Bertagnolli MM
J Thorac Cardiovasc Surg; 2004 Jun; 127(6):1579-86. PubMed ID: 15173710
[TBL] [Abstract][Full Text] [Related]
32. Vascular cell adhesion molecule 1, soluble Fas and hepatocyte growth factor as predictors of mortality in nonagenarians: the Vitality 90+ study.
Kämppä N; Mäkelä KM; Lyytikäinen LP; Peltonen N; Hautamäki J; Seppälä I; Mononen N; Goebeler S; Karhunen PJ; Hervonen A; Hurme M; Jylhä M; Lehtimäki T
Exp Gerontol; 2013 Nov; 48(11):1167-72. PubMed ID: 23911532
[TBL] [Abstract][Full Text] [Related]
33. [The effect of the microenvironment of head and neck cancers on tumor progression].
Lukits J
Magy Onkol; 2009 Mar; 53(1):51-9. PubMed ID: 19318327
[TBL] [Abstract][Full Text] [Related]
34. Serum biomarkers in head and neck squamous cell cancer.
Kaskas NM; Moore-Medlin T; McClure GB; Ekshyyan O; Vanchiere JA; Nathan CA
JAMA Otolaryngol Head Neck Surg; 2014 Jan; 140(1):5-11. PubMed ID: 24232368
[TBL] [Abstract][Full Text] [Related]
35. Angiogenic molecule expression is downregulated in effusions from breast cancer patients.
Konstantinovsky S; Nielsen S; Vyberg M; Kvalheim G; Nesland JM; Reich R; Davidson B
Breast Cancer Res Treat; 2005 Nov; 94(1):71-80. PubMed ID: 16142438
[TBL] [Abstract][Full Text] [Related]
36. Hepatocyte growth factor-activated NF-kappaB regulates HIF-1 activity and ODC expression, implicated in survival, differently in different carcinoma cell lines.
Tacchini L; De Ponti C; Matteucci E; Follis R; Desiderio MA
Carcinogenesis; 2004 Nov; 25(11):2089-100. PubMed ID: 15240510
[TBL] [Abstract][Full Text] [Related]
37. The combination of nuclear factor kappa B, cyclo-oxygenase-2 and vascular endothelial growth factor expression predicts poor prognosis in stage II and III colorectal cancer.
Kim NK; Park JK; Shin E; Kim YW
Anticancer Res; 2014 Nov; 34(11):6451-7. PubMed ID: 25368245
[TBL] [Abstract][Full Text] [Related]
38. High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
Cheng JC; Graber MS; Hsu FM; Tsai CL; Castaneda L; Lee JM; Chang DT; Koong AC
Ann Surg Oncol; 2014 Jul; 21(7):2361-8. PubMed ID: 24623035
[TBL] [Abstract][Full Text] [Related]
39. Serum hepatocyte growth factor and interleukin-6 are effective prognostic markers for non-small cell lung cancer.
Ujiie H; Tomida M; Akiyama H; Nakajima Y; Okada D; Yoshino N; Takiguchi Y; Tanzawa H
Anticancer Res; 2012 Aug; 32(8):3251-8. PubMed ID: 22843899
[TBL] [Abstract][Full Text] [Related]
40. Levels of circulating soluble receptor activator of NF-κB and interleukins-1 predicting outcome of locally advanced basal cell carcinoma.
Lin Q; Li Y; Zhang D; Jin H
Int J Immunopathol Pharmacol; 2016 Dec; 29(4):784-789. PubMed ID: 27760847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
